CASMED Receives FDA Clearance for Next-Gen Vital Signs Monitor, Blood Pressure Solution
CAS Medical Systems, Inc.
(Nasdaq: CASM) (CASMED), a leader in medical devices for non-invasive patient
monitoring, announces receipt of U.S. Food and Drug Administration (FDA)
510(k) clearance for its next-generation 740 SELECT^TM vital signs monitor and
its MAX IQ non-invasive blood pressure technology. The Company expects to
begin fulfilling orders for these products during the third quarter of 2013.
"Our distribution channel has been eagerly awaiting regulatory clearance of
the 740 SELECT, providing state-of-the-art improvements to a 10-year-old
product line," said Thomas M. Patton, President and Chief Executive Officer of
CASMED. "The 740 SELECT has significantly upgraded features, including
touchscreen controls and customizable information displays and is offered with
the newest technology available from our pulse oximetry partners. Our MAX IQ
next generation non-invasive blood pressure platform allows us to offer
various cost effective solutions to our OEM partners. Combined with FDA
clearance of our FORE-SIGHT ELITE Cerebral Oximeter in April, CASMED is now
well-positioned to approach the marketplace with three entirely new products
in the second half of the year."
CASMED's legacy 740^® Monitor is a highly regarded brand known for portability
and performance in rugged environments. Since its introduction in 2003, the
product has enjoyed acceptance around the world, including the sale of more
than 16,000 monitors to the U.S. Veterans Administration alone. The Company's
new 740 SELECT monitor can be configured with various parameters in addition
to MAX IQ non-invasive blood pressure, including predictive temperature,
and/or pulse oximetry solutions, making CASMED monitors ideal for a range of
human and veterinary clinical settings.
"This approval is another significant milestone for CASMED as we execute on
the growth strategy adopted two years ago, and sets the stage to deliver
cutting edge technology to our strengthened distribution channels," Mr. Patton
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.